Approval of FDA PB101phase IND (W.S.S.z. No1110716493) and of application for entry intoTaipei Bioinnovation Park Treatment of eight kinds of solid cancers of stage lV(110DOMA057)/ stage l-lll(110DOMA058) withspecial CIK Innovation Gold Medal Award of Taipei Biotech Awards Treatment of six kinds of solid cancers of phase IV (108DOMA125) and phase l-lll(108DOMA124) with special ClK Obtained the grant of A+ PB103 Industrial Innovative R&D Program. One case of CRO GTP commission ed service cell factory counseling PB103 allogeneic NK preparations IZD approved (No.1096002303) Two cases of CRO GTP commissioned service cell factory counseling Officially applied to FDA (108CONS09319)for allogeneic phase I/lla. SBIR application approved (No10808002261) Obtained "SNQ National Quality Standard Certification and National Biotechnology Medical QualityAward” Passed special control law of Ministry of Health and Welfare for ClK treatment of eight kinds of solid cancers Cell Therapy Technology Institute, Japan TABP passed FDA GTP check. lt signed a contract with the National Defense Medical Center. Approval of Industrial Development Bureau of Ministry of Economic Affairs. Technical Authorization FDA IND Approva/GTP Checked Completed the phase I clinical trial plan. Technical cooperation with OBl Pharma Angel Business Plan of National Development Foundation. Trial production of GTP laboratory in Taipei Medical University,Signed a contract withTaipei Medica University and planned the annual implementation case. The company was founded.
